-
Je něco špatně v tomto záznamu ?
Cilostazol suppresses LPS-stimulated maturation of DC2.4 cells through inhibition of NF-κB pathway
Tianhua Chen, Zhiliang Li, Qiang Fu, Linlin Chen, Longxing Cao, Weiwei Zhang, Jianxin Diao
Jazyk angličtina Země Česko
Typ dokumentu práce podpořená grantem
NLK
Free Medical Journals
od 2003 do 2013
Freely Accessible Science Journals
od 2003 do 2013
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- antigeny CD40 imunologie MeSH
- antigeny CD86 imunologie MeSH
- ateroskleróza imunologie patofyziologie MeSH
- buněčná imunita imunologie účinky léků MeSH
- dendritické buňky * chemie imunologie účinky léků MeSH
- fibrinolytika MeSH
- histokompatibilita - antigeny třídy II imunologie MeSH
- inhibitory agregace trombocytů MeSH
- inhibitory fosfodiesterasy 3 MeSH
- interleukin-6 imunologie MeSH
- lipopolysacharidy terapeutické užití MeSH
- NF-kappa B * genetika imunologie účinky léků MeSH
- polymerázová řetězová reakce MeSH
- průtoková cytometrie MeSH
- techniky in vitro MeSH
- tetrazoly * farmakologie imunologie MeSH
- TNF-alfa imunologie MeSH
- vazodilatancia MeSH
- western blotting MeSH
- Publikační typ
- práce podpořená grantem MeSH
Cilostazol is a phosphodiesterase-3 inhibitor that functions as a platelet aggregation inhibitor and is used for treating peripheral artery diseases and ischemic stroke. Dendritic cells (DCs) play an active role in the immunological processes related to atherosclerosis. Cilostazol has anti-atherogenic and anti-inflammatory effects, but the effects of cilostazol on DC maturation remain unknown. The purpose of this study was to determine the effects of cilostazol on lipopolysaccharide (LPS)-induced maturation of DCs. DC2.4 cells were treated with cilostazol for 12 h and subsequently stimulated with LPS to induce maturation. Cilostazol reduced the expression of maturation-associated markers induced by LPS, such as CD40, CD86, and MHCII, improved the endocytotic function, and decreased production of the tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) of these cells. To further elucidate the mechanisms responsible for the inhibition of DC2.4 maturation by cilostazol, we investigated the effect of cilostazol on LPS-stimulated nuclear factor-kappa B (NF-κB) activation. Our results indicated that cilostazol treatment decreased IκBα degradation and inhibited NF-κB p65 translocation, and the inhibitory effects of cilostazol were cAMP-independent. Therefore, inhibition of NF-κB by cilostazol might result in the suppression of DC maturation. In conclusion, cilostazol suppressed LPS-stimulated DC maturation, which might contribute to its anti-atherosclerosis effect.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000299
- 003
- CZ-PrNML
- 005
- 20130226105550.0
- 007
- ta
- 008
- 130104s2012 xr d f 000 0eng||
- 009
- AR
- 024 7_
- $a 10.2478/v10136-012-0012-0 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Chen,Tianhua $u Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
- 245 10
- $a Cilostazol suppresses LPS-stimulated maturation of DC2.4 cells through inhibition of NF-κB pathway / $c Tianhua Chen, Zhiliang Li, Qiang Fu, Linlin Chen, Longxing Cao, Weiwei Zhang, Jianxin Diao
- 504 __
- $a Literatura $b 41
- 520 3_
- $a Cilostazol is a phosphodiesterase-3 inhibitor that functions as a platelet aggregation inhibitor and is used for treating peripheral artery diseases and ischemic stroke. Dendritic cells (DCs) play an active role in the immunological processes related to atherosclerosis. Cilostazol has anti-atherogenic and anti-inflammatory effects, but the effects of cilostazol on DC maturation remain unknown. The purpose of this study was to determine the effects of cilostazol on lipopolysaccharide (LPS)-induced maturation of DCs. DC2.4 cells were treated with cilostazol for 12 h and subsequently stimulated with LPS to induce maturation. Cilostazol reduced the expression of maturation-associated markers induced by LPS, such as CD40, CD86, and MHCII, improved the endocytotic function, and decreased production of the tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) of these cells. To further elucidate the mechanisms responsible for the inhibition of DC2.4 maturation by cilostazol, we investigated the effect of cilostazol on LPS-stimulated nuclear factor-kappa B (NF-κB) activation. Our results indicated that cilostazol treatment decreased IκBα degradation and inhibited NF-κB p65 translocation, and the inhibitory effects of cilostazol were cAMP-independent. Therefore, inhibition of NF-κB by cilostazol might result in the suppression of DC maturation. In conclusion, cilostazol suppressed LPS-stimulated DC maturation, which might contribute to its anti-atherosclerosis effect.
- 650 12
- $a tetrazoly $x farmakologie $x imunologie $7 D013777
- 650 _2
- $a inhibitory fosfodiesterasy 3 $7 D058987
- 650 _2
- $a inhibitory agregace trombocytů $7 D010975
- 650 _2
- $a fibrinolytika $7 D005343
- 650 _2
- $a vazodilatancia $7 D014665
- 650 12
- $a dendritické buňky $x chemie $x imunologie $x účinky léků $7 D003713
- 650 _2
- $a ateroskleróza $x imunologie $x patofyziologie $7 D050197
- 650 _2
- $a lipopolysacharidy $x terapeutické užití $7 D008070
- 650 _2
- $a antigeny CD40 $x imunologie $7 D019013
- 650 _2
- $a antigeny CD86 $x imunologie $7 D051940
- 650 _2
- $a histokompatibilita - antigeny třídy II $x imunologie $7 D000949
- 650 12
- $a NF-kappa B $x genetika $x imunologie $x účinky léků $7 D016328
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a polymerázová řetězová reakce $7 D016133
- 650 _2
- $a interleukin-6 $x imunologie $7 D015850
- 650 _2
- $a TNF-alfa $x imunologie $7 D014409
- 650 _2
- $a buněčná imunita $x imunologie $x účinky léků $7 D007111
- 650 _2
- $a techniky in vitro $7 D066298
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Li, Zhiliang $u Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
- 700 1_
- $a Fu,Qiang $u Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
- 700 1_
- $a Chen, Linlin $u Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
- 700 1_
- $a Cao,Longxing $u Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
- 700 1_
- $a Zhang, Weiwei $u Department of Cardiology, The Affiliated Zhujiang Hospital of Southern Medical University, Guangzhou, P. R. China
- 700 1_
- $a Diao, Jianxin $u Symptomatic Laboratory of Traditional Chinese Medical, Southern Medical University, Guangzhou, P. R. China
- 773 0_
- $t Journal of applied biomedicine $x 1214-021X $g Roč. 10, č. 4 (2012), s. 177-186 $w MED00012667
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2012/04/02.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 3 $z 0
- 990 __
- $a 20130104091656 $b ABA008
- 991 __
- $a 20130226105751 $b ABA008
- 999 __
- $a ok $b bmc $g 963036 $s 798458
- BAS __
- $a 3
- BMC __
- $a 2012 $b 10 $c 4 $d 177-186 $i 1214-021X $m Journal of Applied Biomedicine $n J. Appl. Biomed. (Čes. Budějovice Print) $x MED00012667
- LZP __
- $c NLK188 $d 20130226 $a NLK 2013-02/ip
